GAVI Alliance and WHO announce yellow fever and child vacc schemes

20 May 2007

The GAVI Alliance, a partnership of national governments, international agencies and vaccine manufacturers, has announced a $58.0 million donation to a Yellow Fever Initiative in a dozen West African countries that are at high risk of the disease.

In a statement, the GAVI Alliance, which estimates that it has so far contributed to the saving of 2.3 million deaths in developing countries by the end of 2006, noted that widespread immunization programs in some African countries from the 1940s to the 1960s had "resulted in the almost-complete disappearance of yellow fever." However, with the emergence of generations since 1960 with no immunity for the disease, the World Health Organization estimates that in Lagos, Nigeria, alone, one third of the 4.5 million population is vulnerable to a future outbreak of yellow fever.

In separate news, the GAVI Alliance also announced that six developing nations, (Ghana, Guyana, Madagascar, Malawi, Tanzania and Zambia) had contributed, ahead of schedule, to the cost of local child vaccination programs.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight